MedTrace Logo

Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia

NCT07036809 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2026-01-29

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Leukemia (Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)). The main questions it aims to answer are:

What are the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Lymphoblastic Leukemia? What are the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Myeloid Leukemia? Researchers will compare patients with Acute Leukemia (30 with ALL and 30 with AML) to 30 healthy control subjects to see if there are significant differences in the levels of Antithrombin III, Protein C, Protein S, and D-dimer.

Participants will:

Undergo full history and clinical examination. Have routine hematological analysis including Complete Blood Count (CBC), blood film, Erythrocyte sedimentation rate (ESR), Prothrombin Time Test and INR (PT/INR), and partial thromboplastin time (PTT).

Have specific tests for quantitative measurement of Antithrombin III, Protein C, Protein S, and D-dimer.

Undergo Flow cytometry immunophenotyping.

Conditions

Interventions

DIAGNOSTIC_TEST

Antithrombin III

quantitative measurement(%)

DIAGNOSTIC_TEST

Protein C

quantitative measurement(%)

DIAGNOSTIC_TEST

Protein S

quantitative measurement(%)

DIAGNOSTIC_TEST

D-dimer

quantitative measurement( ug/ml)

DIAGNOSTIC_TEST

Flow cytometry immunophenotyping

Flow cytometry immunophenotyping

Sponsors & Collaborators

  • Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2025-10-01
Completion
2025-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07036809 on ClinicalTrials.gov